TrialFrontiers in immunology2025
Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.
Yujun Wei et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.